Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory conditions. For many, it has provided relief when other therapies failed. However, ...
Sanofi delivered strong Q3 results despite currency headwinds. The company's dependence on Dupixent is increasing. A broad immunology pipeline and the Blueprint Medicines acquisition should help ...
Investing.com -- Sanofi reported stronger-than-expected third-quarter results, driven by accelerating demand for its blockbuster drug Dupixent and a wave of new product launches. Shares rose around 3% ...
A 26.2% increase in sales for anti-inflammatory blockbuster Dupixent (dupilumab) ensured Sanofi had a strong Q3, despite the company’s vaccine sales declining amid shifts in US policy. Sanofi is known ...
Sanofi SNY reported third-quarter 2025 adjusted earnings of $1.70 per American depositary share, which beat the Zacks Consensus Estimate of $1.60. Earnings of €2.91 per share rose 7% on a reported ...
The logo of French drugmaker Sanofi is seen a the Sanofi Genzyme Polyclonals in Lyon, France, September 30, 2023. REUTERS/Gonzalo Fuentes LONDON (Reuters) -France's Sanofi reported a third-quarter ...
Below, we’ve compiled answers to some of the most common questions we’ve received about these investigations, the science behind the concerns, and next steps for affected individuals. What is ...
Sanofi SNY and partner Regeneron REGN announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the approval of ...
Hosted on MSN
Sanofi stock slides on Dupixent successor AD trial
Sanofi’s stock dropped in the wake of data from its Phase III trial of atopic dermatitis (AD) candidate amlitelimab, which had been touted as a potential successor to Dupixent. While the Phase III ...
French drugmaker Sanofi SA (NASDAQ:SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match ...
Regeneron Pharmaceuticals ((REGN)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback